Pengaruh Diabetes Melitus Tipe 2 terhadap Sarkopenia pada Lansia

Authors

  • Anindya Rosma Fakultas Kedokteran Universitas Kristen Maranatha
  • Decky Gunawan Bagian Faal Fakultas Kedokteran Universitas Kristen Maranatha
  • Cindra Paskaria Bagian Ilmu Kesehatan Masyarakat Universitas Kristen Maranatha

DOI:

https://doi.org/10.28932/jmh.v4i2.2886

Keywords:

diabetes melitus tipe 2, lansia, sarkopenia

Abstract

Sarkopenia adalah penurunan massa otot dan umum terjadi pada lansia. Sarkopenia dikaitkan dengan proses selular seperti penurunan faktor-faktor anabolisme otot dan peningkatan faktor-faktor inflamasi yang berdampak pada proses katabolisme otot. Terjadinya sarkopenia dikaitkan dengan bermacam-macam faktor risiko, salah satunya adalah diabetes melitus tipe 2 (DM tipe 2). DM adalah penyakit metabolik dengan karakteristik hiperglikemia yang terjadi akibat kelainan sekresi insulin, kerja insulin atau kedua-duanya. Tujuan penelitian ini adalah untuk mengetahui pengaruh DM tipe 2 terhadap sarkopenia pada lansia. Metode penelitian adalah studi observasional analitik dengan desain cross-sectional. Terdapat 60 subjek penelitian yang memenuhi kriteria inklusi dan eksklusi, yang terdiri dari 22 lansia yang menderita DM tipe 2 dan 38 lansia yang tidak menderita DM tipe 2. Analisis data menggunakan uji statistik Chi-Square pada tabel 2x2 dengan α = 0,05. Hasil penelitian menunjukkan bahwa proporsi penderita sarkopenia pada lansia yang menderita DM tipe 2 (61,9 %) lebih banyak daripada lansia yang tidak menderita DM tipe 2 (38,1) dengan nilai p = 0,003. Nilai Odds Ratio sebesar 5,471, menunjukkan bahwa lansia yang memiliki riwayat DM tipe 2 berisiko 5 kali lebih besar mengalami sarkopenia. Dapat disimpulkan terdapat pengaruh DM tipe 2 terhadap sarkopenia pada lansia.

Downloads

Download data is not yet available.

References

Riviati N, Setiati S, Laksmi PW, Abdullah M. Factors Related with Handgrip Strength in Elderly Patients. Acta Med Indones. 2017;49(3):215–9.

Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: Etiology, clinical consequences, intervention, and assessment. Osteoporos Int. 2010;21(4):543–59.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;39(4):412–23.

Malmstrom TK, Morley JE. SARC-F: A simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531–2.

Care D, Suppl SS. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes. Diabetes Care. 2019;42:S13–28.

Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes, Metab Syndr Obes Targets Ther. 2019;12:1057–72.

Khamseh ME, Malek M, Aghili R, Emami Z. Sarcopenia and diabetes: Pathogenesis and consequences. Br J Diabetes Vasc Dis. 2011;11(5):230–4.

Wang T, Feng X, Zhou J, Gong H, Xia S, Wei Q, et al.. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep. 2016;6:1–7.

Vitriana Vitriana, Irma Ruslina Defi, Gaga Nugraha Irawan, Budi Setiabudiawan. Prevalensi Sarkopenia pada Lansia di Komunitas (Community Dwelling) berdasarkan Dua Nilai Cut-off Parameter Diagnosis. MKB. 2016; 48(3)

Morisky DE, Ang A, Wood MK, Ward HJ. Predictive Validity of a Medication Adherence Measure for Hypertension in an Outpatient Setting. Journal Clinical Hypertension. 2008; 5(10): 348–354.

Kim KS, Park KS, Kim MJ, Kim SK, Cho YW, Park SW. Type 2 diabetes is associated with low muscle mass in older adults. Geriatr Gerontol Int. 2014;14(SUPPL.1):115–21.

Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, et al.. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010;33(7):1497–9.

Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenburg J, Nilwik R, et al.. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc [Internet]. 2013;14(8):585–92. Available from: http://dx.doi.org/10.1016/j.jamda.2013.02.006

Jung EY, Seo JW, Lee JH, Suh YS, Kim DH. Association between Sarcopenia and Diabetes according to Age in Korean Adults. KJFP 2016;6:242-248.

Chung SM, Moon JS and Chang MC. Prevalence of Sarcopenia and Its Association With Diabetes: A Meta-Analysis of Community-Dwelling Asian Population. Front. Med. 2021;8:681232.

Al-Haj Mohd MMM, Phung H, Sun J, Morisky DE. Improving adherence to medication in adults with diabetes in the United Arab Emirates. BMC Public Health. 2016;16(1):1–11.

Mokolomban C, Wiyono WI, Mpila DA. Kepatuhan Minum Obat Pada Pasien Diabetes Melitus Tipe 2 Disertai Hipertensi Dengan Menggunakan Metode Mmas-8. Pharmacon. 2018;7(4):69–78.

Wong MCS, Wu CHM, Wang HHX, Li HW, Hui EMT, Lam AT, et al. Association between the 8-item Morisky medication adherence scale (MMAS-8) score and glycaemic control among Chinese diabetes patients. J Clin Pharmacol. 2015;55(3):279–87.

Cetrone M, Mele A, Tricarico D. Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. Curr Diabetes Rev. 2014;10(4):231–7.

Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057-72.

Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect. 2014;2(1): e00028

Ai Y, Xu R, Liu L. The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13(1):93. doi:10.1186/s13098-021-00707-7

Downloads

Published

2022-08-31

How to Cite

1.
Rosma A, Gunawan D, Paskaria C. Pengaruh Diabetes Melitus Tipe 2 terhadap Sarkopenia pada Lansia. J. Med. Health [Internet]. 2022Aug.31 [cited 2024Dec.18];4(2):145-53. Available from: http://114.7.153.31/index.php/jmh/article/view/2886

Issue

Vol. 4 No. 2 (2022)

Section

Articles

License

Copyright (c) 2022 Anindya Rosma, Decky Gunawan, Cindra Paskaria

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain the copyright and grant the journal right of first publication with the work
    simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.